2025 Global Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 Global Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global anti-obesity drugs market are Novo Nordisk, Eli Lilly, Hoffmann-La Roche (Roche), and Pfizer. Novo Nordisk dominates with its semaglutide-based drugs Wegovy and Ozempic, essential in chronic weight management and diabetes, supported by strong global sales and recent FDA approvals. Eli Lilly competes strongly with tirzepatide-based drugs Mounjaro and Zepbound, which have shown superior efficacy in clinical trials and are projected to surpass Novo Nordisk’s sales by 2026. Roche contributes with fat absorption inhibitor Orlistat (Xenical) and significant investments like acquiring Carmot Therapeutics to access innovative obesity drug candidates. Pfizer is also a key player actively advancing its portfolio in obesity drug development through strategic efforts.
These companies are at the forefront of innovation, pushing GLP-1 receptor agonists and combination therapies that not only promote weight loss but also address metabolic health comprehensively. The market is projected to grow exponentially to hundreds of billions by 2030, driven by these leaders' efforts in launching advanced drugs with improved modalities, such as oral formulations and multi-agonists, which enhance patient compliance and efficacy. Geographic markets such as North America, Europe, and Asia Pacific see intense competition among these companies, with growing obesity prevalence fueling demand and investments in R&D, regulatory approvals, and manufacturing capabilities. Constant innovation and new drug launches from these top firms shape the future landscape of anti-obesity treatments worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global anti-obesity drugs market are Novo Nordisk, Eli Lilly, Hoffmann-La Roche (Roche), and Pfizer. Novo Nordisk dominates with its semaglutide-based drugs Wegovy and Ozempic, essential in chronic weight management and diabetes, supported by strong global sales and recent FDA approvals. Eli Lilly competes strongly with tirzepatide-based drugs Mounjaro and Zepbound, which have shown superior efficacy in clinical trials and are projected to surpass Novo Nordisk’s sales by 2026. Roche contributes with fat absorption inhibitor Orlistat (Xenical) and significant investments like acquiring Carmot Therapeutics to access innovative obesity drug candidates. Pfizer is also a key player actively advancing its portfolio in obesity drug development through strategic efforts.
These companies are at the forefront of innovation, pushing GLP-1 receptor agonists and combination therapies that not only promote weight loss but also address metabolic health comprehensively. The market is projected to grow exponentially to hundreds of billions by 2030, driven by these leaders' efforts in launching advanced drugs with improved modalities, such as oral formulations and multi-agonists, which enhance patient compliance and efficacy. Geographic markets such as North America, Europe, and Asia Pacific see intense competition among these companies, with growing obesity prevalence fueling demand and investments in R&D, regulatory approvals, and manufacturing capabilities. Constant innovation and new drug launches from these top firms shape the future landscape of anti-obesity treatments worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
